Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2025)

Keros Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $287.4 million for Q4 2025.

• Quarterly Cash & Equivalents fell 48.67% year-over-year to $287.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $287.4 million (down 48.67% YoY) and the FY2025 annual result came in at $287.4 million, down 48.67% from the prior year.
• Cash & Equivalents was $287.4 million for Q4 2025 at Keros Therapeutics, down from $693.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $720.5 million in Q1 2025 and bottomed at $215.6 million in Q2 2022.
• A 5-year average of $376.5 million and a median of $305.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 368.11% — and 2025, when it plunged 48.67%.
• Keros Therapeutics' Cash & Equivalents stood at $230.0 million in 2021, then gained by 21.3% to $279.0 million in 2022, then increased by 18.67% to $331.1 million in 2023, then surged by 69.09% to $559.9 million in 2024, then plunged by 48.67% to $287.4 million in 2025.
• Business Quant data shows KROS's Cash & Equivalents at $287.4 million in Q4 2025, $693.5 million in Q3 2025, and $690.2 million in Q2 2025.